Should I buy or sell Aquestive Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares. View AQST analyst ratings or view top-rated stocks .

What is Aquestive Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 1 year price objectives for Aquestive Therapeutics' stock. Their AQST share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 142.9% from the stock's current price. View analysts price targets for AQST or view top-rated stocks among Wall Street analysts .

How have AQST shares performed in 2023?

Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST stock has increased by 173.8% and is now trading at $2.47. View the best growth stocks for 2023 here .

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024. View our AQST earnings forecast .

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $11.33 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , Zosano Pharma (ZSAN) , Dynavax Technologies (DVAX) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Organigram (OGI) , Novan (NOVN) , Outlook Therapeutics (OTLK) and KushCo (KSHB) .

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.19%), Acadian Asset Management LLC (0.82%), Connor Clark & Lunn Investment Management Ltd. (0.37%), Walleye Capital LLC (0.23%), GSA Capital Partners LLP (0.15%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd. View institutional ownership trends .

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Aquestive Therapeutics Stock Price, News & Analysis (NASDAQ:AQST)

$2.47

+0.08 (+3.35%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.35
▼
$2.67
50-Day Range: $1.30
▼
$2.47
52-Week Range: $0.72
▼
$2.69

Volume: 1.07 million shs
Average Volume: 381,794 shs
Market Capitalization: $164.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Aquestive Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 142.9% Upside
$6.00 Price Target
Short Interest: Healthy
2.88% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.88
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.07) to ($0.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

679th out of 952 stocks

Pharmaceutical Preparations Industry

318th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Aquestive Therapeutics has a forecasted upside of 142.9% from its current price of $2.47.
Amount of Analyst Coverage
Aquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.88% of the outstanding shares of Aquestive Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aquestive Therapeutics has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Aquestive Therapeutics has recently decreased by 1.54%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aquestive Therapeutics does not currently pay a dividend.
Dividend Growth
Aquestive Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AQST.

3.3

News and Social Media Coverage

News Sentiment
Aquestive Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aquestive Therapeutics this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
14 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.39% of the stock of Aquestive Therapeutics is held by insiders.
Percentage Held by Institutions
Only 30.91% of the stock of Aquestive Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.07) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aquestive Therapeutics is -9.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aquestive Therapeutics is -9.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Aquestive Therapeutics Stock (NASDAQ:AQST)

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AQST Stock News Headlines

November 29, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?

November 28, 2023 | finance.yahoo.com

Best Momentum Stocks to Buy for November 28th

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 27, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know

November 21, 2023 | finance.yahoo.com

Those who invested in Aquestive Therapeutics (NASDAQ:AQST) a year ago are up 90%

November 16, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know

November 13, 2023 | morningstar.com

Aquestive Therapeutics Inc AQST

November 10, 2023 | finance.yahoo.com

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 9, 2023 | benzinga.com

Aquestive Therapeutics Stock (NASDAQ:AQST), Analyst Ratings, Price Targets, Predictions

November 8, 2023 | markets.businessinsider.com

Positive Outlook for Aquestive Therapeutics: Early Trial Start, Surpassing Financial Expectations and Successful Debt Refinancing

November 8, 2023 | finance.yahoo.com

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call Transcript

November 6, 2023 | finance.yahoo.com

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023 | finance.yahoo.com

Aquestive Therapeutics Inc (AQST) Reports 25% Year-Over-Year Growth in Year-to-Date Revenue

November 3, 2023 | msn.com

Canaccord believes Rani restructuring will help speed development

November 3, 2023 | benzinga.com

Preview: Aquestive Therapeutics's Earnings

November 2, 2023 | finance.yahoo.com

Aquestive Therapeutics Completes $45 Million Debt Refinancing

November 1, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

October 31, 2023 | finance.yahoo.com

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET

October 24, 2023 | msn.com

Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know

October 11, 2023 | msn.com

Wedbush Reiterates Aquestive Therapeutics (AQST) Outperform Recommendation

October 10, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Aquestive Therapeutics (AQST), Guardant Health (GH)

October 9, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

October 9, 2023 | markets.businessinsider.com

FDA Approvals and Strong Business Performance Reinforce Buy Rating for Aquestive Therapeutics

October 4, 2023 | finance.yahoo.com

Aquestive Therapeutics (AQST) Stock Moves -0.71%: What You Should Know

September 22, 2023 | msn.com

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

September 21, 2023 | markets.businessinsider.com

Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)

See More Headlines

Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/05/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AQST
CUSIP: N/A
CIK: 1398733
Web: www.aquestive.com
Phone: (908) 941-1900
Fax: N/A
Employees: 130
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $8.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +142.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,410,000.00
Net Margins: -25.20%
Pretax Margin: -24.90%
Return on Equity: N/A
Return on Assets: -20.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.76
Quick Ratio: 1.47

Sales & Book Value

Annual Sales: $47.68 million
Price / Sales: 3.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.19) per share
Price / Book: -1.13

Miscellaneous

Outstanding Shares: 66,770,000
Free Float: 61,165,000
Market Cap: $164.92 million
Optionable: Not Optionable
Beta: 2.73

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Daniel Barber (Age 47)
CEO, President & Director
Comp: $925.35k
Mr. Alexander Mark Schobel (Age 64)
Chief Innovation & Technology Officer
Comp: $672.69k
Ms. Lori J. Braender BSBA (Age 67)
Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $678.76k
Mr. A. Ernest Toth Jr. (Age 64)
Chief Financial Officer
Comp: $679.9k
Ms. Cassie Jung (Age 44)
Senior Vice President of Operations
Mr. Peter E. Boyd (Age 57)
Senior Vice President of IT, HR & Communications
Mr. Kenneth W. Marshall (Age 64)
Chief Commercial Officer
Dr. Gary H. Slatko M.D. (Age 66)
MBA, Chief Medical Officer
Dr. Stephen Wargacki (Age 45)
Senior VP of Research & Development
Dr. Carl N. Kraus M.D. (Age 53)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AQST Stock Analysis - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings or view top-rated stocks.
What is Aquestive Therapeutics' stock price target for 2024?: 3 Wall Street research analysts have issued 1 year price objectives for Aquestive Therapeutics' stock. Their AQST share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for AQST or view top-rated stocks among Wall Street analysts.
How have AQST shares performed in 2023?: Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST stock has increased by 173.8% and is now trading at $2.47.
View the best growth stocks for 2023 here.
When is Aquestive Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our AQST earnings forecast.
How were Aquestive Therapeutics' earnings last quarter?: Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $11.33 million.

What other stocks do shareholders of Aquestive Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).
When did Aquestive Therapeutics IPO?: (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.
Who are Aquestive Therapeutics' major shareholders?: Aquestive Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.19%), Acadian Asset Management LLC (0.82%), Connor Clark & Lunn Investment Management Ltd. (0.37%), Walleye Capital LLC (0.23%), GSA Capital Partners LLP (0.15%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd.
View institutional ownership trends.
How do I buy shares of Aquestive Therapeutics?: Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AQST) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial